ATE318137T1 - Parenteral anzuwendendes bisphosphonathaltiges arzneimittel - Google Patents

Parenteral anzuwendendes bisphosphonathaltiges arzneimittel

Info

Publication number
ATE318137T1
ATE318137T1 AT01900452T AT01900452T ATE318137T1 AT E318137 T1 ATE318137 T1 AT E318137T1 AT 01900452 T AT01900452 T AT 01900452T AT 01900452 T AT01900452 T AT 01900452T AT E318137 T1 ATE318137 T1 AT E318137T1
Authority
AT
Austria
Prior art keywords
bisphosphooneate
product containing
medicinal product
parenteral application
parenteral
Prior art date
Application number
AT01900452T
Other languages
English (en)
Inventor
Anke Diederich
Pierre Goldbach
Thomas Pfister
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE318137T1 publication Critical patent/ATE318137T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01900452T 2000-01-20 2001-01-16 Parenteral anzuwendendes bisphosphonathaltiges arzneimittel ATE318137T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00101044 2000-01-20

Publications (1)

Publication Number Publication Date
ATE318137T1 true ATE318137T1 (de) 2006-03-15

Family

ID=8167661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01900452T ATE318137T1 (de) 2000-01-20 2001-01-16 Parenteral anzuwendendes bisphosphonathaltiges arzneimittel

Country Status (29)

Country Link
US (1) US6677320B2 (de)
EP (1) EP1251857B1 (de)
JP (1) JP3933933B2 (de)
KR (1) KR100518391B1 (de)
CN (1) CN1311835C (de)
AR (1) AR027245A1 (de)
AT (1) ATE318137T1 (de)
AU (1) AU779677B2 (de)
BR (1) BR0107755A (de)
CA (1) CA2406798C (de)
CY (1) CY1106482T1 (de)
CZ (1) CZ301961B6 (de)
DE (1) DE60117362T2 (de)
DK (1) DK1251857T3 (de)
ES (1) ES2258070T3 (de)
HR (1) HRP20020594B1 (de)
HU (1) HU229054B1 (de)
IL (2) IL150549A0 (de)
MA (1) MA26865A1 (de)
MX (1) MXPA02007057A (de)
NO (1) NO329930B1 (de)
NZ (1) NZ519881A (de)
PL (1) PL199784B1 (de)
PT (1) PT1251857E (de)
RS (1) RS50166B (de)
RU (1) RU2238736C2 (de)
SI (1) SI1251857T1 (de)
WO (1) WO2001052859A1 (de)
ZA (1) ZA200205241B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
ITTO20020406A1 (it) * 2002-05-13 2003-11-13 Chiesi Farma Spa Formulazioni di bisfosfonati ad uso iniettabile.
PL377878A1 (pl) * 2003-01-17 2006-02-20 Teva Pharmaceutical Industries Ltd. Sól sodowa rizedronianu o bardzo niskiej zawartości żelaza
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
AU2005275193A1 (en) * 2004-07-15 2006-02-23 Nanobac Life Sciences Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses
US20060069068A1 (en) * 2004-07-15 2006-03-30 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by pathological calcification
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
ATE495747T1 (de) * 2004-08-23 2011-02-15 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
UA91204C2 (ru) * 2004-12-02 2010-07-12 Ману Чаудхарі Композиция для преодоления опосредствованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенная для инъекции
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
RU2387661C2 (ru) * 2005-02-01 2010-04-27 Ф.Хоффманн-Ля Рош Аг Полиморфная модификация в ибандроната
US7714158B2 (en) * 2005-02-01 2010-05-11 Hoffmann-La Roche Inc. Ibandronate polymorph
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2006102117A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
US20070088161A1 (en) * 2005-10-19 2007-04-19 Stockel Richard F Novel chelated bisphosphonates for use as pharmaceutical agents
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
US20070264130A1 (en) * 2006-01-27 2007-11-15 Phluid, Inc. Infusion Pumps and Methods for Use
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
US20090023683A1 (en) * 2007-07-16 2009-01-22 Chandrasekhar Kocherlakota Complexes comprising zoledronic acid and cyclodextrins
CN101835496B (zh) 2007-10-23 2015-11-25 尼克塔治疗公司 靶向羟基磷灰石的多臂聚合物以及由其制造的偶联物
US8986253B2 (en) * 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
CN101530415A (zh) * 2008-03-10 2009-09-16 北京德众万全医药科技有限公司 一种含有双膦酸盐的药物组合物及其制备方法
US20090287180A1 (en) * 2008-05-19 2009-11-19 Diperna Paul M Disposable pump reservoir and related methods
CA2665501A1 (en) * 2008-09-02 2010-03-02 Ohio University Methods and compositions for the treatment and prevention of bone loss
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) * 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
EP2180003A1 (de) * 2008-10-21 2010-04-28 Zentiva, k.s. Herstellung von Trinatriumbandronat
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
KR101813728B1 (ko) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2826548A1 (en) * 2010-02-06 2011-08-11 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012054807A2 (en) 2010-10-22 2012-04-26 President And Fellows Of Harvard College Vaccines comprising bisphosphonate and methods of use thereof
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
GB201200868D0 (en) * 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
CN103070824B (zh) * 2013-01-24 2014-07-16 天津红日药业股份有限公司 一种含有伊班膦酸钠的注射液
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
CN103385882B (zh) * 2013-07-03 2016-02-24 江苏奥赛康药业股份有限公司 一种伊班膦酸钠注射用组合物
CN105232451B (zh) * 2015-09-27 2019-02-05 青岛斯蒂朗机电设备有限公司 一种含有唑来膦酸的注射用组合物
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型
RU2657833C2 (ru) 2015-12-01 2018-06-15 Общество С Ограниченной Ответственностью "Остерос Биомедика" Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и её применение
EA033181B1 (ru) * 2015-12-09 2019-09-30 Общество С Ограниченной Ответственностью "Остерос Биомедика" Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и ее применение
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
EA030671B1 (ru) 2016-07-20 2018-09-28 Общество С Ограниченной Ответственностью "Остерос Биомедика" Препарат для лечения костных поражений, вызванных злокачественными новообразованиями

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4252742A (en) 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
DE3428524A1 (de) 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
DE3512536A1 (de) 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
CA1339805C (en) 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4958839A (en) 1988-07-12 1990-09-25 Guzik Technical Enterprises, Inc. Disc clamp employing resilient cone for spreading balls
US4922077A (en) 1989-01-31 1990-05-01 Raytheon Company Method of laser marking metal packages
CA2035179C (en) 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
DE4244423A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Wasserlösliche Calciumsalze der 1-Hydroxy-3-(methylpentylamino)propan-1,1-bisphosphonsäure, ihre Herstellung und Verwendung als Arzneimittel
DE4244422A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel
US5462932A (en) 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
JP3672342B2 (ja) * 1994-09-26 2005-07-20 アステラス製薬株式会社 ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US5730715A (en) * 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients

Also Published As

Publication number Publication date
EP1251857A1 (de) 2002-10-30
PL357675A1 (en) 2004-07-26
CA2406798C (en) 2008-04-29
SI1251857T1 (sl) 2006-06-30
AU2516501A (en) 2001-07-31
CN1311835C (zh) 2007-04-25
BR0107755A (pt) 2002-11-12
JP3933933B2 (ja) 2007-06-20
IL150549A0 (en) 2003-02-12
MXPA02007057A (es) 2002-12-13
RS50166B (sr) 2009-05-06
HU229054B1 (en) 2013-07-29
NO20023469D0 (no) 2002-07-19
NO20023469L (no) 2002-07-19
IL150549A (en) 2007-06-03
MA26865A1 (fr) 2004-12-20
HRP20020594B1 (en) 2011-03-31
JP2003520240A (ja) 2003-07-02
ES2258070T3 (es) 2006-08-16
CY1106482T1 (el) 2012-01-25
ZA200205241B (en) 2003-09-29
AU779677B2 (en) 2005-02-03
DE60117362T2 (de) 2006-10-05
CN1396830A (zh) 2003-02-12
US6677320B2 (en) 2004-01-13
AR027245A1 (es) 2003-03-19
EP1251857B1 (de) 2006-02-22
KR20020073509A (ko) 2002-09-26
DK1251857T3 (da) 2006-05-08
NZ519881A (en) 2005-08-26
RU2238736C2 (ru) 2004-10-27
CZ301961B6 (cs) 2010-08-11
NO329930B1 (no) 2011-01-24
DE60117362D1 (de) 2006-04-27
PT1251857E (pt) 2006-06-30
US20010011082A1 (en) 2001-08-02
PL199784B1 (pl) 2008-10-31
YU54802A (sh) 2006-01-16
CA2406798A1 (en) 2001-07-26
KR100518391B1 (ko) 2005-09-29
WO2001052859A1 (en) 2001-07-26
HRP20020594A2 (en) 2004-08-31
HUP0204114A2 (hu) 2003-03-28
HUP0204114A3 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
ATE318137T1 (de) Parenteral anzuwendendes bisphosphonathaltiges arzneimittel
ATE240732T1 (de) Ziprasidonhaltige arzneimittel
ATE380814T1 (de) Kinaseinhibitoren als arzneimittel
DE69900162T2 (de) Arzneimittel enthaltend Oxaliplatin
DE60115698D1 (de) Medikamentenspender
NO20015510L (no) Medikament for lokal påföring
DE60109530D1 (de) Amorphe Mupirocin enthaltende Arzneimittel
GB0031084D0 (en) Pharmaceutical compounds
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20014926L (no) Farmasöytiske forbindelser
ITMI20001827A0 (it) Medicamento antinfiammatorio
ATE359085T1 (de) Arzneimittel enthaltend aktiviertes antithrombin iii
ATE269337T1 (de) Trizyclische delta3-pyridine als arzneimittel
DE60008237D1 (de) Lamivudin enthaltende arzneimittel
GB0019272D0 (en) Pharmaceutical compounds
GB0024318D0 (en) Pharmaceutical compounds
GB0005366D0 (en) Pharmaceutical compounds
ATA12192000A (de) Antimykotisch wirkendes arzneimittel
DE69819203D1 (de) Trinkbares arzneimittel
UA4469S (uk) Упаковка для ліків
UA4809S (uk) Упаковка для ліків
UA4470S (uk) Упаковка для ліків
UA4815S (uk) Упаковка для ліків
UA4806S (uk) Упаковка для ліків
UA4807S (uk) Упаковка для ліків

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1251857

Country of ref document: EP